Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results
Cancer
 

Click here to go back to your search results.

Melanoma treatment details. Biologic therapy. Chemotherapy. Memorial Sloan-Kettering Cancer Center, New York, NY, United States



Survival: 11.2 months
   
Toxicity Grade: 4
   
Treatments: Biologic therapy
Chemotherapy
   
Drugs:
Country: United States
   
City/State/Province: New York, NY
   
Hospital: Memorial Sloan-Kettering Cancer Center
   
Journal: Link
   
Date: 6/2011

Description:
Patients:
In this study, patients with previously untreated metastatic melanoma were divided into 2 separate treatment groups. Group A consisted of 250 patients with a median age of 57.5 years, 60.8% of whom were male. There were 252 patients in group B with a median age of 56.4 years and 59.1% were male.

Treatment:
Patients in group A were treated with the chemotherapy agent dacarbazine and the biologic therapy agent ipilimumab, a monoclonal antibody that blocks a protein called CTLA-4 and helps the immune system target cancer cells. Group B was treated with dacarbazine and a placebo (sugar pill).

Toxicity:
The maximum reported toxicity in group A was of grade 4, including increased liver enzymes, fatigue, and shortness of breath.

There was 1 treatment-related death reported for group B due to gastrointestinal hemorrhage. Grade 4 vomiting, abdominal pain, fatigue, and weakness were also reported.

Results:
The median overall survival for groups A and B was 11.2 and 9.1 months, respectively.

Support:
This study was supported by Bristol Myers Squibb, makers of ipilimumab (brand name Yervoy).

Correspondence: Dr. Jedd D. Wolchok; email: wolchokj@mskcc.org

E-mail to a Friend Email Physician More Information